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The concept of the haematopoietic stem cell (HSC) niche was formulated by Schofield in the 1970s, as a region within the
bone marrow containing functional cell types that can maintain HSC potency throughout life. Since then, ongoing research has
identified numerous cell types and a plethora of signals that not only maintain HSCs, but also dictate their behaviour with respect
to homeostatic requirements and exogenous stresses. It has been proposed that there are endosteal and vascular niches within the
bone marrow, which are thought to regulate diﬀerent HSC populations. However, recent data depicts a more complicated picture,
with functional crosstalk between cells in these two regions. In this review, recent research into the endosteal/vascular cell types
and signals regulating HSC behaviour are considered, together with the possibility of a single subcompartmentalised niche.
1. Introduction
Haematopoietic stem cells (HSCs) are a heterogeneous group
of multipotent stem cells that have the ability to self-renew
and diﬀerentiate into all the functional blood cell types of
the body. During vertebrate development, the first source
of haematopoiesis is extraembryonic haemangioblasts. These
cells predominantly generate erythrocytes and endothelial
cells to supply the emerging yolk sac vasculature and have
diﬀerent properties to HSCs of the adult which arise later in
development [1]. For this review, HSCs will be considered
as cells able to confer long-term myeloid and lymphoid
multilineage haematopoiesis. Transplantation studies in the
mouse have demonstrated that the first HSCs that satisfy this
definition emerge during the development of the embryonic
blood vessels from a subset of cells called the haemogenic
endothelium [2–4]. The HSCs then colonise the fetal liver,
where there is HSC expansion and the appearance of chara-
cteristic cell surfacemarkers of adult HSCs [5, 6]. Late in fetal
development, HSCs home and engraft in the bone marrow,
where they reside throughout adult life [7]. The bone mar-
row is the main site of adult haematopoiesis, although during
times of stress haematopoiesis may also occur in the spleen
and liver.
Amultitude of studies have identified numerous intrinsic
pathways that regulate HSC self-renewal and diﬀerentiation
programmes [8]. However, in the 1970s, it was noted that
whilst HSCs in the bone marrow drive haematopoiesis
throughout the life of organisms, when they are removed
from the bonemarrow, they lose the ability to self renew indi-
cating the equal dependence of HSCs on extrinsic signals [9].
This led Schofield to propose the “niche” hypothesis, which
states that HSCs require the support of other cell types in the
bone marrow to maintain HSC potency [9]. It is now clear
that other than simply maintaining HSCs, the niche plays
important roles in regulating the behaviour of HSCs with
respect to homeostasis and responses to exogenous stresses.
For example, under normal conditions most HSCs in the
bone marrow are dormant or slowly cycling, which prevents
stem cell exhaustion and maintains haematopoiesis [10, 11].
However, under periods of haematopoietic stress such as
blood loss, HSCs and progenitors are activated to proliferate
and diﬀerentiate to replace the lost cells [12].
Schofield’s recognition of the HSC niche has fostered
ongoing research trying to identify and understand the cell-
ular and molecular components that make up the niche. At
present, there is broad discussion of the possible presence
of two bone marrow niches able to maintain and regulate
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HSCs, which are the endosteal and vascular niches. However,
whether these environments truly represent two distinct HSC
niches still remains under debate.
2. The Endosteal Niche
The endosteum is the interface between bone and bone mar-
row. This region is lined with a heterogeneous group of
osteoblastic cells at various stages of diﬀerentiation, only a
fraction of which are fully mature osteoblasts able to synthe-
sise bone. Osteoclasts, which are bone-absorbing cells, also
line the endosteum and dynamically balance bone formation
with the osteoblasts. Several lines of investigation have point-
ed to the importance of osteoblastic cells in maintaining
and supporting HSCs in the niche. The coculture of HSCs
and osteoblast cell lines in vitro results in an expansion of
HSC numbers indicating enhanced ex vivo self-renewal [13].
Similarly, increasing the number of osteoblastic cells in vivo
correlates with an increase in the number of HSCs [14, 15].
In addition, the cotransplantation of osteoblasts with HSCs
in mice significantly enhances engraftment [16].
Osteoblastic cells synthesise a number of cytokines that
appear to contribute to the maintenance and regulation of
HSCs by the endosteal niche. These include thrombopoi-
etin (THPO) and angiopoietin (Ang-1), which bind to cell
surface receptors MPL and Tie2, respectively, which are ex-
pressed on HSCs. These cytokines are thought to be impor-
tant as THPO and Ang-1 knockout mice have decreased
numbers or defects in bone marrow HSCs [17–19]. In agree-
ment with these data, stimulation of the MPL receptor with
THPO enhances the quiescence of long term (LT)-HSCs,
whilst inhibition of the receptor decreases their quiescence
[20]. The THPO/MPL pathway is thought to promote quies-
cence by activating cyclin-dependent kinase inhibitors
(CDKIs) such as p57kip2 [21]. The interaction of Ang-1 with
its receptor Tie2 has also been shown to enhance quiescence
and maintain long term repopulating ability of HSCs, whilst
protecting against apoptosis by activating the PI3K pathway
[22].
Besides secreting important cytokines, osteoblastic cells
also express a range of membrane-bound ligands and adhe-
sion receptors which contribute to the maintenance of HSCs
within the endosteal niche. Osteoblastic cells express Jagged,
a ligand for Notch receptors expressed on HSCs. Activation
of Notch receptors on HSCs has been shown to inhibit diﬀer-
entiation and enhance their self renewal capacity in vitro [23,
24]. Conversely, in vivo Notch deletion studies failed to show
any significant eﬀects of Notch signalling on HSC diﬀer-
entiation and self renewal, making the role of Notch in the
niche controversial [25, 26]. However, it has been recently
demonstrated that Notch2 knockout mice have a reduced
ability to recover from bone marrow injury induced by 5-
fluorouracil (5-FU) treatment as well as a decrease in re-
populating HSCs in the bonemarrow [27]. This suggests that
Notch signalling is important in vivo for controlling HSC self
renewal and diﬀerentiation during haematopoietic stress
conditions and is masked by other factors or is redundant
during homeostasis.
N-Cadherin is a calcium-dependent homophilic adhe-
sion molecule [28], which is expressed on both immature
and mature osteoblastic cell populations. Like the Jagged/
Notch pathway, the role of N-Cadherin in the endosteal niche
remains controversial [29, 30]. In some mouse studies nei-
ther N-Cadherin mRNA nor protein could be detected in
HSCs [31], whereas other studies report its expression in
both ST-HSCs and LT-HSCs [32, 33]. The N-Cadherin
knock-out mouse has no apparent defects in HSC activity or
haematopoiesis, indicating that HSCs do not depend on
N-Cadherin for maintenance in vivo [34]. However, HSCs
that express a dominant negative mutant N-Cadherin have a
reduced ability to anchor to the endosteum and consequently
a diminished capacity to repopulate bone marrow following
transplantation [32]. Therefore, the role of N-Cadherin in
the endosteal niche remains uncertain, but it seems to have
a role in enhancing endosteal-HSC interactions following
bone marrow transplantation.
Chemokines and their receptors control HSC behaviour
by regulating migration, homing, and release of HSCs within
the bone marrow. The best-understood chemokine is
stromal-derived factor-1 (SDF-1) also called chemokine C-
X-C motif ligand 12 (CXCL12). The SDF-1 receptor is the
C-X-C chemokine receptor type 4 (CXCR4) and is expressed
on HSCs and progenitors. The importance of SDF-1/CXCR4
signalling has been demonstrated by both SDF-1−/− and
CXCR4−/− mice, which have severe defects in myelopoiesis,
including a decreased number of myeloid progenitors within
the bone marrow [35, 36]. SDF-1 is secreted by a variety of
cells within the bone marrow including osteoblasts, endo-
thelial cells, and scattered stromal cells [37], but it has
recently been reported that osteoblasts are high secretors of
SDF-1 [38]. In agreement with these data the authors found
that the HSC-mobilising cytokine G-CSF exerts its long term
eﬀects partly by decreasing osteoblast activity resulting in
reduced endosteal SDF-1 levels [38].
Although osteoblastic cells are the most studied in terms
of HSC maintenance within the endosteal niche, many other
types of cells are present. Increasing evidence suggests that
bone-degrading osteoclasts play an important role in regu-
lating HSCs within the bone marrow. The degradation of
bone by osteoclasts releases factors embedded in the bone
matrix. These include transforming growth factor beta 1
(TGF beta 1), bone morphogenic proteins (BMPs), and
calcium ions [39–41]. TGF beta 1, BMP-2, and BMP-7 have
been demonstrated to enhance the quiescence and mainte-
nance of HSCs in vitro [39, 40], whilst evidence suggests
that calcium ions enhance the retention of HSCs to the
endosteal surface [42]. In support of these data, mice treated
with bisphosphonates, which inhibit osteoclast reabsorbing
activity, have diminished numbers of LT-HSCs within the
bone marrow coupled with reduced HSC quiescence and
enhanced diﬀerentiation [43].
Accumulating evidence now indicates that tissue-specific
macrophages play important roles in supporting the devel-
opment of a variety of tissues [44]. Macrophages termed
osteomacs are found at the endosteum in close proximity to
osteoblasts and osteoclasts [45]. Osteomacs regulate osteo-
blast function and are required for optimal mineralisation
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in vitro and in vivo [45]. Depletion of osteomacs in vivo also
results in decreased numbers of osteoblasts and a reduction
in osteoblast-secreted cytokines such as Ang-1, KIT ligand,
and CXCL12 [46]. These changes are accompanied by the
mobilisation of HSCs from the bone marrow, indicating a
central role for osteomacs in maintaining the structure and
function of the endosteal niche [46]. An important unan-
swered question is whether osteomacs interact directly with
HSCs within the endosteal niche.
3. Sympathetic Innervation of the HSC Niche
A complex organisation of neuronal fibres are found within
the bone marrow, and sympathetic nervous system (SNS)
activity has been reported to control bone formation [47,
48]. However, more recently, a potential role of SNS activity
in the endosteal niche has been identified. Frenette and col-
leagues demonstrated that sulphogalactoceramide (sul-
fatide), a sulpholipid synthesised by ceramide galactosytrans-
ferase (CGT) in neuronal Schwann cells, could mobilise
HSCs from the bone marrow [49]. To investigate the eﬀects
of sulfatide depletion on the endosteal niche andHSCmobil-
isation, a CGT knockout mouse was created. As expected,
CGT−/− mice showed hematopoietic defects and decreased
HSC mobilisation in response to G-CSF administration, but
unexpectedly this was not directly due to impaired sulfatide
release [50, 51]. Rather, the decreased ability of the CGT−/−
mice to mobilise HSCs in response to G-CSF was found to
be due to impairment of the neuronal signals that regulate
osteoblast function [51]. The authors went on to demon-
strate that sympathetic nervous system activity suppresses
osteoblast function resulting in enhanced HSC mobilisation
from the bone marrow [51].
4. The Vascular Niche
Several lines of evidence suggest that vascular environments
are involved in the maintenance of HSCs as well as endosteal
environments. During fetal development, fetal functioning
HSCs first arise from the haemogenic endothelium of the
vasculature, indicating that the two tissues are developmen-
tally closely related [2–4]. Fetal HSCs then reside in the liver
and the spleen, where early haematopoiesis takes place in the
absence of osteoblasts or the endosteal niche [5, 6]. Even
in adults, HSCs are present in the liver and the spleen
throughout life and are capable of extramedullary haem-
atopoiesis [52, 53]. These observations indicate that cells of
vascular environments can both support HSCs and regulate
their self renewal and diﬀerentiation.
The bone marrow is heavily vascularised; the medullary
artery feeds in to arterioles, capillaries, and then the sinu-
soids. Sinusoids are specialised blood vessels, which have thin
walls with a fenestrated arrangement of endothelial cells to
allow the passage of haematopoietic cells [54]. The sinusoids
form an extensive network throughout the bonemarrow, and
therefore the endothelial cells which make up the sinusoids
are important when considering HSC bone marrow niche.
This idea has been supported by mouse endothelial cell and
HSC co-culture experiments, which demonstrate that some
endothelial cell populations can support the expansion of
HCSs in vitro [55, 56]. As well as this, some endothelial
cell populations can maintain severe combined immune-
deficient (SCID) mouse repopulating capacity of HSCs dur-
ing co-culture, [57, 58].
Important recent work indicates that endothelial cells are
important for haematopoiesis in vivo. Yao and colleagues
sought to investigate whether the reduced numbers of HSCs
and defects in haematopoiesis of gp130 knockout mice [59]
were directly due to eﬀects onHSCs or due to eﬀects on niche
endothelial cells [60]. Mice expressing Cre recombinase
under control of the Tie2 promoter, which is active in HSCs
and endothelial cells, were crossed with mice containing a
gp130 gene with loxP sites. The resulting mice had a condi-
tional deletion of gp130 in both HSCs and endothelial cells.
These mice appeared normal at birth but had hypocellular
bone marrow, developed expanded sinusoidal spaces, and
died prematurely at around 1 year. Transplantation of bone
marrow from gp130 deficient mice into normal irradiated
mice restored normal haematopoiesis. However, transplanta-
tion of bone marrow from normal mice into gp130-deficient
irradiated mice did not restore normal haematopoiesis.
These complimentary transplantation experiments indicate
that endothelial cells are essential components of the HSC
niche and that endothelial gp130 signalling is crucial for
maintaining haematopoiesis [60].
Other evidence indicates that many HSCs are located
near the sinusoids in the bone marrow. It has been suggested
that the rapid mobilisation of HSCs within minutes of
administering G-CSF argues that a large proportion of HSCs
must be very close to blood vessels [61, 62]. More recently,
Kiel and colleagues identified a group of markers called sig-
nalling lymphocyte activation molecule (SLAM) family
markers which include CD150, CD244, and CD48, which
are diﬀerentially expressed between HSC and progenitor
subpopulations in mice [63]. The most immature HSCs
could be precisely identified as CD150+ve, CD244−ve, and
CD48−ve, allowing reliable imaging of HSCs within the bone
marrow for the first time [31, 63]. Strikingly, they found that
around 60% of HSCs defined in this way were in contact with
the endothelium of sinusoids, whereas, only around 20%
were found at the endosteal surface. Overall only 10% of the
total bone marrow nucleated cells were found at the sinusoid
endothelium, indicating a 6-fold selective enrichment of
HSCs in this area. Whilst these results point to a distinct
vascular niche for HSCs within the bone marrow, virtually
all HSCs (92–95%) were also found within 5 cell diameters
from the sinusoid endothelium. Thus, it remains possible
that HSCs at the endosteum are also eﬀected by vascular cells
[31].
Reticular cells are a group of cells that are located
around the sinusoid endothelium and are important in the
homing and localisation of HSCs within the bone marrow.
These cells have recently been shown to be high secretors of
SDF-1 (CXCL12), and as a result have been named CXCL12
abundant reticular (CAR) cells [64]. By using immunohisto-
chemical analysis of the bonemarrow of CXCL12-GFP knock
in mice, Sugiyama and colleagues have shown that nearly all
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(97%) of HSCs within the bone marrow were localized to
CAR cells. Interestingly, 100% of the HSCs located at the
endosteumwere also located to CAR cells. These data suggest
that CAR cells are crucial for the homing of HSCs in both the
vascular and endosteal niches and together with the data of
Kiel and colleagues, indicate that functionally there may be
just one class of niche in the bone marrow.
Further data from Omatsu et al. (2010) suggests that
CAR cells are important in supporting the proliferation of
HSCs/progenitors as selective ablation of CAR cells resulted
in a reduction in the number of cycling progenitors, and
enhanced the quiescence of HSCs in the bone marrow [65].
As well as this, CAR cells were found to be high secretors of
the proproliferative cytokine stem cell factor (SCF), and that
CAR cell ablation resulted in a decreased in SCF levels [65].
The authors went on to show that CAR cells express adipo-
genic and osteogenic genes and can diﬀerentiate into adipo-
cytes and osteoblasts in vitro. These data suggest that CAR
cells are a form of adipo-osteogenic progenitor derived from
mesenchymal stem cells [65]. Mesenchymal stem cell (MSC)
was a term proposed by Caplan in 1991 [66] to describe the
multipotent bone marrow stromal cell populations, which
Owen and Friedenstein demonstrated in the 1960s and 1970s
to be capable of undergoing osteoblastic diﬀerentiation to
form bone [67]. Whether MSCs truly represent a stem cell
capable of self renewal and multipotency on a single cell
basis is not proven in vivo [68]. However, their participation
in supporting the vascular HSC niche is better established,
specifically CD146+ve cells that are found in the subendothe-
lial layers of sinusoids [69]. Bone marrow-derived CD146+ve
cells are capable of diﬀerentiating in vitro along multiple
lineages to form osteoblasts, chondrocytes, and adipocytes,
which is considered characteristic of MSCs [70], but only
CD146+ve cells (and not other MSC-like populations) have
been demonstrated conclusively and clonally to recapitulate
the haematopoietic microenvironment and synthesise bone
when transplanted heterotopically [69]. HSCs are also better
supported in vitro by MSCs derived from bone marrow than
MSCs derived from other tissues, for example from adipose
tissue [71]. CD146+ve bone marrow cells express a variety of
factors that support HSCs, including Jagged-1, N cadherin,
stem cell factor (SCF), and SDF-1 [69].
Megakaryocytes have been implicated to be involved in
regulating haematopoiesis, since mice with decreased mature
megakaryocytes and platelets have other haematopoietic
defects such as anaemia and myelofibrosis [72, 73]. However,
the contribution of megakaryocytes in regulating HSCs by
direct or indirect mechanisms is poorly understood. Mega-
karyocytes are located close to sinusoidal endothelial cells in
the perivascular environment [74, 75], and data also suggests
that they communicate with the endosteal niche. Co-cul-
ture of megakaryocytes and osteoblasts in vitro enhances
osteoblast proliferation up to 6-fold, a mechanism requiring
direct cell contact [76–78]. These data are supported by in
vivo studies, using NF-E2 knockout mice, which have an
accumulation of megakaryocytes and an increase in bone
mass and osteoblasts [76, 79]. Kacena and colleagues [80]
transplanted spleen cells from NF-E2−/− mice into irradiated
mice and after 4 weeks found the same megakaryocytic and
osteoblastic phenotype as the donor NF-E2−/− mice. These
data suggest that the increase in bone mass and osteoblasts
seen in the NF-E2−/− mice is an indirect feature, caused by
an increase in megakaryocytes [80].
Recent data suggests that megakaryocytes and platelets
directly regulate the behaviour of HSCs. Like HSCs, mega-
karyocytes and their precursors express Mpl, the receptor for
TPO, and as the name thrombopoietin suggests, signalling
via this pathway is necessary for megakaryocytic diﬀerentia-
tion and platelet formation [81, 82]. Serum TPO levels inver-
sely correlate with megakaryocyte mass suggesting that TPO
levels are regulated by the amount of cells which can take
up and remove TPO from the circulation via Mpl [83, 84].
This provokes an interesting question whether megakary-
ocytes regulate the levels of available TPO and consequently
regulate HSC quiescence. De Graaf and colleagues [85] inves-
tigated this possibility by creating myb and p300 mutations
in mice that lead to an increase in megakaryocytes and plate-
lets. As expected, these mutants had decreased serum TPO
levels, and a striking change in TPO responsive genes in
bone marrow HSCs. Furthermore, the authors found that
this resulted in increased HSC cycling consistent with the
decreased TPO levels. The authors conclude that the TPO
regulates megakaryocytic diﬀerentiation, which in turn regu-
lates circulating TPO levels and quiescence of HSCs [85].
This feedback mechanism could be important to maintain
homeostasis during injury. For example, increased bleeding
would cause a decrease in platelets resulting in an increase
in circulating TPO. The increased TPO could then not only
drive diﬀerentiation of megakaryocytic precursors to replace
the lost platelets, but also enhance the quiescence of LT-HSCs
to prevent stem cell exhaustion and protect future haema-
topoiesis. These data provide exciting new evidence that
HSCs are regulated by their mature progeny, a process which
has been poorly studied but has to be important to guide
haematopoiesis with respect to the levels ofmature cell popu-
lations.
5. Evidence for an Adult Haemangioblast
The relationship and proximity of HSCs to sinusoidal endo-
thelial cells provoke the question whether adults have haem-
angioblasts and haemogenic endothelial cells which can
renew HSC within adult bone marrow. In humans, CD34 is a
marker expressed on both HSCs and endothelial progenitor
cell populations. HSCs and endothelial progenitors are fur-
ther enriched within the CD34+ve and vascular endothelial
growth factor receptor 2 (KDR+ve) population, whilst HSCs
only are found within the CD34+ve/KDR−ve fraction [86].
Pelosi and colleagues used limiting dilution assays to show
that 5% of cells within the CD34+ve/KDR+ve fraction could
give rise to both haematopoietic and endothelial lineages,
indicative of haemangioblast activity [86]. Coupled with this,
it has been suggested that some HSCs expressing CD34 and
leukocyte marker CD45 have haemangioblast activity in vivo,
as transplantation of these cells into mice results in donor-
derived vascularisation [87]. However, the transplantation of
a small contaminating population of endothelial progenitors
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cannot be fully ruled out in this study. These studies
are supported by investigations in chronic myeloid leuka-
emia (CML), a clonal malignancy arising in the HSC com-
partment, characterised by expression of the BCR:ABL
fusion gene. Endothelial cells from CML patients have been
found that express the BCR:ABL fusion gene, suggesting that
endothelial cells and HSCs have a common ancestor [88].
However, the location of the adult haemangioblasts within
the bone marrow niche is unknown, as well as its contribu-
tion to renewing the HSC pool. Also, unlike in the embryo,
an adult haemogenic endothelium with the potential to give
rise to HSCs has not yet been discovered.
6. The Role of Small Bioactive Signalling
Molecules in the HSC Niche
The majority of research into signalling mechanisms within
the bone marrowmicroenvironment has focussed on protein
molecules such as cytokines, chemokines, adhesion mole-
cules, and their prospective receptors. However, small non-
protein bioactive molecules such as eicosanoids are emerging
as essential signalling mediators regulating HSC behaviour
within the niche. Eicosanoids are a group of 20 carbon fatty
acids that are derived from arachidonc acid and include;
prostacyclins, prostaglandins, thromboxanes, endocannabi-
noids, and leukotrienes. Eicosanoids are synthesised by a
wide range of cells and have diverse eﬀects [89].
Prostaglandins are the best understood eicosanoids, and
of which prostaglandin E2 (PGE2) is the most studied in
terms of modulating HSC behaviour. PGE2 synthesis is
a two-step process; COX-1 and COX-2 enzymes convert
arachidonic acid into prostaglandin H2 (PGH2), which is
further converted to PGE2 by prostaglandin synthases. PGE2
is secreted by eﬄux transporters called multi-drug resistance
proteins (MDRP), where it can act as an autocrine or para-
crine signal by binding to G-protein-coupled E prostanoid
(EP) receptors. Four diﬀerent EP receptors for PGE2 have
been identified (EP1 to EP4) [90], and all four of these have
been shown to be expressed on both murine and human
HSCs [91]. Evidence suggests that PGE2 is secreted by a vari-
ety of cell types which are found in the bone marrow includ-
ing; osteoblasts [92–94], monocytes/macrophages [95, 96],
and sinusoidal endothelial cells [97, 98]. Therefore, PGE2 is
likely to be found in both endosteal and vascular niches.
In seminal studies from North et al. [99], a chemical
genetic screen was used to identify important factors reg-
ulating HSC formation during zebrafish embryogenesis. It
was found that chemicals that increased PGE2 synthesis, such
as linoleic acid, also increased HSC numbers, whilst COX
inhibitors, such as celecoxib, decreased HSC numbers. In
agreement with the screen, exogenous use of a stable deriva-
tive of PGE2, 16,16-dimethyl-PGE2 (dmPGE2), increased
HSC formation during embryogenesis and enhanced the
haematopoietic recovery of irradiated adult zebrafish. In
murine models, treatment of HSCs with dmPGE2 in vitro
also enhanced HSC repopulating capacity following trans-
plantation into irradiated mice [99]. Follow-up experiments
demonstrated that PGE2 signalling enhanced HSC wnt
signalling associated with increased HSC proliferation [100].
Others found that PGE2 increased the expression of survivin
in HSCs, an antiapoptotic protein which enhances HSC
survival as well as progression through cell cycle [91]. In
addition to this, PGE2 has been found to increase CXCR4
expression on HSCs, thereby enhancing migration to SDF-1
and homing to the bone marrow [91, 101].
Although these studies provide some of the first enticing
evidence of the role of PGE2 in the HSC niche, surprisi-
ngly little is known about the involvement of other eico-
sanoids. Data suggests that prostaglandin D2 (PGD2),
another derivative of PGH2, is themajor prostaglandin in the
bone marrow [102], but its eﬀects on HSCs remain largely
uninvestigated. Leukotriene synthesis has also been shown in
the bone marrow [103], and there is evidence that leuko-
trienes can stimulate myeloid progenitor proliferation
in vitro [104]. Therefore, further research is needed to shed
light on the role of the array of small bioactive signalling
molecules within the HSC niche.
7. The Role of Hypoxia in the HSC Niche
As well as the cells and other factors that make up bone mar-
row microenvironments, other physiological characteristics
of the niche need to be considered, of which hypoxia is
emerging as vital in regulating HSC behaviour. The oxygen
levels of the bone marrow vary considerably, as areas close
to sinusoids are highly perfused, whereas areas further away
around the endosteum are poorly perfused and hypoxic. In
vitro studies demonstrated that haematopoiesis is enhanced
by low oxygen levels of around 1%, giving suggestive evi-
dence that this may be the case in vivo [105, 106]. In agree-
ment with these data, mathematical modelling approaches
pointed to hypoxic environments for the location of HSCs in
the bone marrow [107].
Until recently, the study of hypoxia in the bone marrow
was hampered by its complex organisation and inaccessibil-
ity. Parmar and colleagues 2007 [108], used Hoechst dye (a
DNA-intercalating dye that is readily taken up by live cells)
to measure the perfusion of cell populations within the bone
marrow. Mice were intravenously infused with a pulse of
Hoechst, and then uptake into cells in the bone marrow
was measured using flow cytometry. They found a striking
broad continuum in the amount of Hoechst taken up with
variability in the range of 1000-fold. Furthermore, cells that
had taken up the least amount of Hoechst exhibited HSC-like
properties in long-term culture initiating assays and highest
engraftment frequency in irradiated mice [108].
Winkler et al. [109] built on the above results by anal-
ysing not only Hoechst perfusion but also the cell surface
markers expressed on HSCs and on more mature progeni-
tors. As expected, they found that the most immature HSCs
were Hoechst negative and only these cells could reconstitute
haematopoietic system in serial transfer experiments [109].
As only dormant HSCs are able to serially engraft [110], it
suggests that HSCs away from sinusoid perfusion contain
the most potent and dormant HSCs. The authors also found
a phenotypically identical (by surface marker expression)
6 Stem Cells International
Sympathetic
neural fibres Osteoblast Ang-1
Adhesion
receptors
TPO
Osteomac
Osteoclast
BMPs,
Ca2+ ions
and TGFβ Megakaryocyte
Endothelial cell
SDF
Eicosanoids
SinusoidHSC
SCF
CAR cell
SDF
O2 levels
Figure 1: Endosteal and vascular niches are subcompartments of a single niche. HSCs located at the endosteum are more quiescent and
have a greater self-renewal capacity due to a variety of cytokines, adhesion molecules, and hypoxia. HSCs located close to the sinusoid
endothelium have reduced self-renewal capacity and are cycling more rapidly, due to higher oxygen levels and SCF. However, nearly all HSCs
reside adjacent to CAR cells and in close proximity to the sinusoid endothelium. The cells of the vascular niche communicate with cells of
the endosteal niche, and the subtle balance of factors from these subcompartments governs the behaviour of the HSCs.
population of Hoechst medium cells, which had ability to
reconstitute haematopoiesis only in primary recipients [109].
The association of the more potent HSCs with a hypoxic
environment may be linked to protection from reactive
oxygen species (ROS). When oxygen is metabolised, ROS are
released as a byproduct, causing DNA damage and protein
miss folding, which have been associated with ageing [111].
Elevating ROS in the haematopoietic system, by creation
of ataxia-telangiectasia-mutated-(ATM-) knockout mice,
results in progressive bone marrow failure [112]. In agree-
ment with these data, HSCs with low ROS levels have been
shown to maintain potency throughout serial transplan-
tation experiments, when compared to HSCs with high
ROS levels [113]. Other than causing cellular damage, data
suggests that ROS activates the P38 MAPK pathway, which
decreases adhesion molecule expression and enhances cell
cycle progression [112, 114, 115]. Collectively, these data
indicate that hypoxia in the endosteal niche protects HSCs
against ROS-induced damage, whilst maintaining niche-
HSC interactions and quiescence. This is necessary to
maintain HSC self renewal capacity and protect against stem
cell exhaustion, whilst the higher oxygen levels in the vascular
niche may facilitate progenitor proliferation.
8. Concluding Remarks
More than 30 years of research has uncovered an astonish-
ingly complex array of signals within the bonemarrow niche,
the subtle balance of which dictates the behaviour of HSCs.
Distinct endosteal and vascular environments have been
identified, where generally speaking the endosteal niche sup-
ports quiescent HSCs, whereas the vascular niche facilitates
the proliferation of more mature progenitors. However, even
HSCs at the endosteum reside within 5 cell diameters of
sinusoids [31], and virtually all endosteal HSCs are adjacent
to CAR cells associated with the sinusoid endothelium [64].
Coupled with this, the endosteal niche cannot maintain ade-
quate haematopoiesis in mice where the vascular niche has
been compromised [60], supporting the accumulating data
describing crosstalk and overlap between cells in these two
compartments. Consequently, these data reveal that the
endosteal/vascular two niches hypothesis is far too basic and
possibly should be thought of as subcompartments of a single
niche (Figure 1). The advent of novel technologies that now
permit the study of the niche in three dimensions and in real
time will no doubt accelerate the solution of this problem
[116, 117]. Even so, there is still much to learn about the
HSC niche with new avenues including, the role of maturing
cells in guiding haematopoiesis with respect to biological
need, the eﬀect of small bioactive molecules on HSCs, and
functions of the adult haemangioblasts in replenishing the
HSC pool.
The knowledge gained from studying the HSC niche
has important implications for health and disease. The use
of cord blood HSCs to treat disorders in adults has been
hampered by their relatively small numbers and shortcom-
ings in expansion techniques of current ex vivo culture sys-
tems. Further understanding of the factors involved in regu-
lating self renewal and proliferation of HSCs in the niche,
would allow these to bemimicked in vitro, thereby enhancing
expansion of HCS prior to transplantation. On the other side
of the coin, the quiescence of leukaemic stem cells (LSCs)
renders them largely unresponsive to current chemothera-
peutic agents, leading to disease relapse. Understanding the
myriad factors regulating HSC quiescence and how these sig-
nals are perturbed in leukaemia are therefore important to
enable the future development of therapies to eradicate
LSCs.
Stem Cells International 7
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